We are hiring! Three positions available - Head Scientist (Life Sciences), Senior Scientist (Life Sciences) and Senior Software Engineer. Please see our careers page for details.
Nucleotrace accepted onto FDA Emerging Technologies Program to develop applications for oral and injectable pharmaceuticals.
Nucleotrace awarded highly competitive grant from the Victorian Medical Research Acceleration Fund for work on cannabis and pharmaceuticals.
Nucleotrace takes out multiple awards at Tech23 in Sydney, including -
The Innovation Excellence Award for the company whose technology demonstrates the highest level of innovation and originality
The Addison's Award for the most backable team
The Deep Technology Award presented by Cicada Innovations
Nucleotrace technology has wide spread applications across all consumable products. Our current focus applications are pharmaceuticals and medicinal cannabis. In June 2019, Nucleotrace was accepted onto the FDA Emerging Technologies Program.
Counterfeit pharmaceuticals are responsible for one million deaths and cost the industry $200 billion each year. Nucleotrace has developed the first product-integrated supply chain monitoring technology for pharmaceuticals that tracks each ingredient over its entire life cycle. Information such as the batch number, expiry date and manufacturing facility is stored inside each tablet as a non-toxic molecular fingerprint.
Compliance. Meets core objectives outlined in the Drug Supple Chain Security Act (DSCSA) and FDA/APEC Supply Chain Toolkit.
Serialisation compatible. Seamless integration into product serialisation platforms.
Secure. Nucleotrace technology creates an immutable link between product, package and database (centralized, decentralized or distributed).
Safe. Very small amounts of DNA oligonucleotide are used which is pharmacologically inactive and whose safety is supported by industry regulators.
Inexpensive. Economically viable for cheap generic drugs.
Coverage. 100% unbroken supply chain coverage from raw ingredients to finished product.
Tracing resolution. Traceability to the smallest unpackaged dosage unit (tablet), not just package.
Harmonised data sharing. Information transfers are harmonised between product ingredients, finished product, package and single point of contact (SPOC) database.
Rapid parallel sample processing. Up to 200 product samples can be processed in <1.5 hours which is suitable for auditing at points of sale and ports of entry.
Portable testing. Compatibility with new DNA sequencing technology will soon permit real-time smartphone based sample processing without the need for laboratory access.
Product-integrated information. When a product is mixed or split information is automatically merged or forked.
Simple. Removes burden on moving parts of supply chain (e.g. individuals responsible for commissioning / decommissioning serial numbers – in the case of product serialization).
Forensic capabilities. Last legitimate node traceback permits identification of leaking/fraudulent nodes from product alone (e.g. products sold illegally, recombined/used in illicit drugs).